Last reviewed · How we verify
MGN1703 treatment
MGN1703 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.
MGN1703 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity. Used for Colorectal cancer (Phase 3), Non-small cell lung cancer (Phase 2).
At a glance
| Generic name | MGN1703 treatment |
|---|---|
| Also known as | dSLIM |
| Sponsor | Mologen AG |
| Drug class | TLR9 agonist |
| Target | TLR9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MGN1703 is a synthetic oligodeoxynucleotide containing unmethylated CpG motifs that bind to TLR9 on immune cells, particularly B cells and plasmacytoid dendritic cells. This activation triggers innate immune signaling pathways that promote interferon-alpha production and enhance both innate and adaptive anti-tumor immune responses. It is designed to be used as an immunotherapeutic agent to boost the body's natural anti-cancer defenses.
Approved indications
- Colorectal cancer (Phase 3)
- Non-small cell lung cancer (Phase 2)
Common side effects
- Flu-like symptoms
- Fatigue
- Fever
- Injection site reactions
Key clinical trials
- Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (PHASE1)
- Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment (PHASE3)
- Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC (PHASE2)
- Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection (PHASE1, PHASE2)
- Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |